Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020
Abstract Objectives To investigate the levels of MDR in the predominant serotypes of invasive Streptococcus pneumoniae isolated in Canada over a 10 year period. Methods All isolates were serotyped and had antimicrobial susceptibility testing performed, in accordance with CLSI guidelines (M07-11 Ed.,...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2023-05, Vol.78 (Supplement_1), p.i17-i25 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | i25 |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | i17 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 78 |
| creator | Adam, Heather J Karlowsky, James A Baxter, Melanie R Schellenberg, John Golden, Alyssa R Martin, Irene Demczuk, Walter Mulvey, Michael R Zhanel, George G |
| description | Abstract
Objectives
To investigate the levels of MDR in the predominant serotypes of invasive Streptococcus pneumoniae isolated in Canada over a 10 year period.
Methods
All isolates were serotyped and had antimicrobial susceptibility testing performed, in accordance with CLSI guidelines (M07-11 Ed., 2018). Complete susceptibility profiles were available for 13 712 isolates. MDR was defined as resistance to three or more classes of antimicrobial agents (penicillin MIC ≥2 mg/L defined as resistant). Serotypes were determined by Quellung reaction.
Results
In total, 14 138 invasive isolates of S. pneumoniae were tested in the SAVE study (S. pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy in Canada), a collaboration between the Canadian Antimicrobial Resistance Alliance and Public Health Agency of Canada—National Microbiology Laboratory. The rate of MDR S. pneumoniae in SAVE was 6.6% (902/13 712). Annual rates of MDR S. pneumoniae decreased between 2011 and 2015 (8.5% to 5.7%) and increased between 2016 and 2020 (3.9% to 9.4%). Serotypes 19A and 15A were the most common serotypes demonstrating MDR (25.4% and 23.5% of the MDR isolates, respectively); however, the serotype diversity index increased from 0.7 in 2011 to 0.9 in 2020 with a statistically significant linear increasing trend (P |
| doi_str_mv | 10.1093/jac/dkad066 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2809004379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkad066</oup_id><sourcerecordid>2809004379</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-eff0df66081eeb7751ca11c176c9a15f557b1150dfc562068534620d0530750b3</originalsourceid><addsrcrecordid>eNp9kL1OwzAYRS0EoqUwsSNPCAlCP8e1nbBVpfxIICQKrJFjOyIliYOdDNl4B96QJyGlhZHpDvfcOxyEDgmcE4jpeCnVWL9JDZxvoSGZcAhCiMk2GgIFFogJowO05_0SADjj0S4aUEH6KuJDVEwrWXQ-99hm-P7yEecVbl4Nrp3RtswrWTV40ThTN1ZZpVqP68q0pa1yabA3zjZdbfxqNZOV1PLiZ72Yvsyxb1rdneEQCPn6-AwhhH20k8nCm4NNjtDz1fxpdhPcPVzfzqZ3gaIhNIHJMtAZ5xARY1IhGFGSEEUEV7EkLGNMpISwnlGMh8AjRid9amAUBIOUjtDJ-rd29r01vknK3CtTFLIytvVJGEEMMKEi7tHTNaqc9d6ZLKldXkrXJQSSld6k15ts9Pb00ea4TUuj_9hfnz1wvAZsW__79A0QwIJP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2809004379</pqid></control><display><type>article</type><title>Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Adam, Heather J ; Karlowsky, James A ; Baxter, Melanie R ; Schellenberg, John ; Golden, Alyssa R ; Martin, Irene ; Demczuk, Walter ; Mulvey, Michael R ; Zhanel, George G</creator><creatorcontrib>Adam, Heather J ; Karlowsky, James A ; Baxter, Melanie R ; Schellenberg, John ; Golden, Alyssa R ; Martin, Irene ; Demczuk, Walter ; Mulvey, Michael R ; Zhanel, George G</creatorcontrib><description>Abstract
Objectives
To investigate the levels of MDR in the predominant serotypes of invasive Streptococcus pneumoniae isolated in Canada over a 10 year period.
Methods
All isolates were serotyped and had antimicrobial susceptibility testing performed, in accordance with CLSI guidelines (M07-11 Ed., 2018). Complete susceptibility profiles were available for 13 712 isolates. MDR was defined as resistance to three or more classes of antimicrobial agents (penicillin MIC ≥2 mg/L defined as resistant). Serotypes were determined by Quellung reaction.
Results
In total, 14 138 invasive isolates of S. pneumoniae were tested in the SAVE study (S. pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy in Canada), a collaboration between the Canadian Antimicrobial Resistance Alliance and Public Health Agency of Canada—National Microbiology Laboratory. The rate of MDR S. pneumoniae in SAVE was 6.6% (902/13 712). Annual rates of MDR S. pneumoniae decreased between 2011 and 2015 (8.5% to 5.7%) and increased between 2016 and 2020 (3.9% to 9.4%). Serotypes 19A and 15A were the most common serotypes demonstrating MDR (25.4% and 23.5% of the MDR isolates, respectively); however, the serotype diversity index increased from 0.7 in 2011 to 0.9 in 2020 with a statistically significant linear increasing trend (P < 0.001). In 2020, MDR isolates were frequently serotypes 4 and 12F in addition to serotypes 15A and 19A. In 2020, 27.3%, 45.5%, 50.5%, 65.7% and 68.7% of invasive MDR S. pneumoniae were serotypes included in the PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccines, respectively.
Conclusions
Although current vaccine coverage of MDR S. pneumoniae in Canada is high, the increasing diversity of serotypes observed among the MDR isolates highlights the ability of S. pneumoniae to rapidly evolve.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkad066</identifier><identifier>PMID: 37130586</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Anti-Bacterial Agents - pharmacology ; Canada - epidemiology ; Humans ; Microbial Sensitivity Tests ; Pneumococcal Infections - microbiology ; Pneumococcal Vaccines ; Serogroup ; Serotyping ; Streptococcus pneumoniae</subject><ispartof>Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i17-i25</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-eff0df66081eeb7751ca11c176c9a15f557b1150dfc562068534620d0530750b3</citedby><cites>FETCH-LOGICAL-c320t-eff0df66081eeb7751ca11c176c9a15f557b1150dfc562068534620d0530750b3</cites><orcidid>0000-0002-1788-1794</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37130586$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adam, Heather J</creatorcontrib><creatorcontrib>Karlowsky, James A</creatorcontrib><creatorcontrib>Baxter, Melanie R</creatorcontrib><creatorcontrib>Schellenberg, John</creatorcontrib><creatorcontrib>Golden, Alyssa R</creatorcontrib><creatorcontrib>Martin, Irene</creatorcontrib><creatorcontrib>Demczuk, Walter</creatorcontrib><creatorcontrib>Mulvey, Michael R</creatorcontrib><creatorcontrib>Zhanel, George G</creatorcontrib><title>Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Abstract
Objectives
To investigate the levels of MDR in the predominant serotypes of invasive Streptococcus pneumoniae isolated in Canada over a 10 year period.
Methods
All isolates were serotyped and had antimicrobial susceptibility testing performed, in accordance with CLSI guidelines (M07-11 Ed., 2018). Complete susceptibility profiles were available for 13 712 isolates. MDR was defined as resistance to three or more classes of antimicrobial agents (penicillin MIC ≥2 mg/L defined as resistant). Serotypes were determined by Quellung reaction.
Results
In total, 14 138 invasive isolates of S. pneumoniae were tested in the SAVE study (S. pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy in Canada), a collaboration between the Canadian Antimicrobial Resistance Alliance and Public Health Agency of Canada—National Microbiology Laboratory. The rate of MDR S. pneumoniae in SAVE was 6.6% (902/13 712). Annual rates of MDR S. pneumoniae decreased between 2011 and 2015 (8.5% to 5.7%) and increased between 2016 and 2020 (3.9% to 9.4%). Serotypes 19A and 15A were the most common serotypes demonstrating MDR (25.4% and 23.5% of the MDR isolates, respectively); however, the serotype diversity index increased from 0.7 in 2011 to 0.9 in 2020 with a statistically significant linear increasing trend (P < 0.001). In 2020, MDR isolates were frequently serotypes 4 and 12F in addition to serotypes 15A and 19A. In 2020, 27.3%, 45.5%, 50.5%, 65.7% and 68.7% of invasive MDR S. pneumoniae were serotypes included in the PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccines, respectively.
Conclusions
Although current vaccine coverage of MDR S. pneumoniae in Canada is high, the increasing diversity of serotypes observed among the MDR isolates highlights the ability of S. pneumoniae to rapidly evolve.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Canada - epidemiology</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Pneumococcal Infections - microbiology</subject><subject>Pneumococcal Vaccines</subject><subject>Serogroup</subject><subject>Serotyping</subject><subject>Streptococcus pneumoniae</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1OwzAYRS0EoqUwsSNPCAlCP8e1nbBVpfxIICQKrJFjOyIliYOdDNl4B96QJyGlhZHpDvfcOxyEDgmcE4jpeCnVWL9JDZxvoSGZcAhCiMk2GgIFFogJowO05_0SADjj0S4aUEH6KuJDVEwrWXQ-99hm-P7yEecVbl4Nrp3RtswrWTV40ThTN1ZZpVqP68q0pa1yabA3zjZdbfxqNZOV1PLiZ72Yvsyxb1rdneEQCPn6-AwhhH20k8nCm4NNjtDz1fxpdhPcPVzfzqZ3gaIhNIHJMtAZ5xARY1IhGFGSEEUEV7EkLGNMpISwnlGMh8AjRid9amAUBIOUjtDJ-rd29r01vknK3CtTFLIytvVJGEEMMKEi7tHTNaqc9d6ZLKldXkrXJQSSld6k15ts9Pb00ea4TUuj_9hfnz1wvAZsW__79A0QwIJP</recordid><startdate>20230503</startdate><enddate>20230503</enddate><creator>Adam, Heather J</creator><creator>Karlowsky, James A</creator><creator>Baxter, Melanie R</creator><creator>Schellenberg, John</creator><creator>Golden, Alyssa R</creator><creator>Martin, Irene</creator><creator>Demczuk, Walter</creator><creator>Mulvey, Michael R</creator><creator>Zhanel, George G</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1788-1794</orcidid></search><sort><creationdate>20230503</creationdate><title>Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020</title><author>Adam, Heather J ; Karlowsky, James A ; Baxter, Melanie R ; Schellenberg, John ; Golden, Alyssa R ; Martin, Irene ; Demczuk, Walter ; Mulvey, Michael R ; Zhanel, George G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-eff0df66081eeb7751ca11c176c9a15f557b1150dfc562068534620d0530750b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Canada - epidemiology</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Pneumococcal Infections - microbiology</topic><topic>Pneumococcal Vaccines</topic><topic>Serogroup</topic><topic>Serotyping</topic><topic>Streptococcus pneumoniae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adam, Heather J</creatorcontrib><creatorcontrib>Karlowsky, James A</creatorcontrib><creatorcontrib>Baxter, Melanie R</creatorcontrib><creatorcontrib>Schellenberg, John</creatorcontrib><creatorcontrib>Golden, Alyssa R</creatorcontrib><creatorcontrib>Martin, Irene</creatorcontrib><creatorcontrib>Demczuk, Walter</creatorcontrib><creatorcontrib>Mulvey, Michael R</creatorcontrib><creatorcontrib>Zhanel, George G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adam, Heather J</au><au>Karlowsky, James A</au><au>Baxter, Melanie R</au><au>Schellenberg, John</au><au>Golden, Alyssa R</au><au>Martin, Irene</au><au>Demczuk, Walter</au><au>Mulvey, Michael R</au><au>Zhanel, George G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2023-05-03</date><risdate>2023</risdate><volume>78</volume><issue>Supplement_1</issue><spage>i17</spage><epage>i25</epage><pages>i17-i25</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Abstract
Objectives
To investigate the levels of MDR in the predominant serotypes of invasive Streptococcus pneumoniae isolated in Canada over a 10 year period.
Methods
All isolates were serotyped and had antimicrobial susceptibility testing performed, in accordance with CLSI guidelines (M07-11 Ed., 2018). Complete susceptibility profiles were available for 13 712 isolates. MDR was defined as resistance to three or more classes of antimicrobial agents (penicillin MIC ≥2 mg/L defined as resistant). Serotypes were determined by Quellung reaction.
Results
In total, 14 138 invasive isolates of S. pneumoniae were tested in the SAVE study (S. pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy in Canada), a collaboration between the Canadian Antimicrobial Resistance Alliance and Public Health Agency of Canada—National Microbiology Laboratory. The rate of MDR S. pneumoniae in SAVE was 6.6% (902/13 712). Annual rates of MDR S. pneumoniae decreased between 2011 and 2015 (8.5% to 5.7%) and increased between 2016 and 2020 (3.9% to 9.4%). Serotypes 19A and 15A were the most common serotypes demonstrating MDR (25.4% and 23.5% of the MDR isolates, respectively); however, the serotype diversity index increased from 0.7 in 2011 to 0.9 in 2020 with a statistically significant linear increasing trend (P < 0.001). In 2020, MDR isolates were frequently serotypes 4 and 12F in addition to serotypes 15A and 19A. In 2020, 27.3%, 45.5%, 50.5%, 65.7% and 68.7% of invasive MDR S. pneumoniae were serotypes included in the PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccines, respectively.
Conclusions
Although current vaccine coverage of MDR S. pneumoniae in Canada is high, the increasing diversity of serotypes observed among the MDR isolates highlights the ability of S. pneumoniae to rapidly evolve.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37130586</pmid><doi>10.1093/jac/dkad066</doi><orcidid>https://orcid.org/0000-0002-1788-1794</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i17-i25 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2809004379 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Anti-Bacterial Agents - pharmacology Canada - epidemiology Humans Microbial Sensitivity Tests Pneumococcal Infections - microbiology Pneumococcal Vaccines Serogroup Serotyping Streptococcus pneumoniae |
| title | Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A36%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20MDR%20in%20the%20predominant%20Streptococcus%20pneumoniae%20serotypes%20in%20Canada:%20the%20SAVE%20study,%202011%E2%80%932020&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Adam,%20Heather%20J&rft.date=2023-05-03&rft.volume=78&rft.issue=Supplement_1&rft.spage=i17&rft.epage=i25&rft.pages=i17-i25&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkad066&rft_dat=%3Cproquest_cross%3E2809004379%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2809004379&rft_id=info:pmid/37130586&rft_oup_id=10.1093/jac/dkad066&rfr_iscdi=true |